Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, ...

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "A case of adenosquamous pancreatic ...

Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the trea ...

Recent research from the University of Helsinki sheds new light on the behavior of the KRAS gene in two of the deadliest cancers—pancreatic and colorectal cancer. These findings suggest ...

Batsmen have forgotten to play with soft hands because in T20 cricket they are used to muscling the ball, says head coach ...

If approved, Verastem expects that avutometinib plus defactinib will be the first-ever FDA-approved treatment specifically for adult patients in the United States with recurrent KRAS mutant LGSOC.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the ...

Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the ...

“ALTA3263 induces deep and durable tumor regressions in preclinical models addicted to the most common KRAS mutations, G12D, G12V, and G12C,” said Eric Murphy, Ph.D., co-founder and CEO of ...

Verastem Oncology submits NDA to US FDA for avutometinib plus defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer: Boston Monday, November 4, 2024, 14:00 Hrs ...